Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 26, 2024 8:10pm
90 Views
Post# 36332521

RE:RE:RE:RE:SABC 2024 - Irene Study Results - Pelareorep in TNBC

RE:RE:RE:RE:SABC 2024 - Irene Study Results - Pelareorep in TNBCThanks notable for the clarification.
i read that same report this am, before posting my reply.
Obviously phase one was a sucsess, or ohase 2 would not have started.
and
clearky there will be reasonable results posted in the Dec symposium,
As I said, they would not waste time, money & energy to publish, BAD results.
yes, Bucky I am important.
I helped over 4000 students , over many years. I was on 2 B.O.D.
and my name is on record with the Canadian red seal, queens printer as trade advisor. For curriculum modernization.
and,over a period of seven years, Formed an environmental group. We worked with levels of government to protect & expand very sensitive environmental land.conservation area.
I have negotiated with .V.Ps , welcomed by cabinet ministers. Our group was recognized in first reading of an environmentalist bill, I co- authored with two local MPPs.
My name is on a dedication, plaque at the mentioned Conservation area.
so, yes, I have been around. In most cases, working very hard to give back & help our world.
Our community group raised & donated over 1/4 million $$, 
i alongside my family & our very dedicated board, worked extremely hard for 7 years.
My only personal take , was my name on the dedication rock.
so, bucfuster,  what have you ever done other than post personal bashing trash?
Back to Onc?
We look forward to discovering what is happening with IRENE trial, I read Dec 3 ish there will be a poster presentation.
Obviously Onc needs a partner or buyout. With Merck set to buyout Incyte, perhaps they could be a wild card?
Roche has long ongoing relationship with oncolytics. One never knows, with buyouts, mergers or other business deals.
answer needed soon.




<< Previous
Bullboard Posts
Next >>